Differentiation of low-molecular-weight heparins: Practical implications

被引：4

作者：

Fareed, J

Bick, R

机构：

[1] Loyola Univ, Med Ctr, Thrombosis & Hemostasis Labs, Maywood, IL 60153 USA

[2] Univ Texas, SW Med Ctr, Dallas, TX 75231 USA

来源：

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 2004年 / 10卷 / 04期

关键词：

D O I：

10.1177/107602960401000401

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：299 / 300

页数：2

共 14 条

[1]

[Anonymous], AM J HOSP PHARM

[2] Low molecular weight heparins: Differences and similarities in approved preparations in the United States [J].

Bick, RL ;

Fareed, J .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 :S63-S66

[3]

Fareed J, 1998, Can J Cardiol, V14 Suppl E, p28E

[4] Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile [J].

Fareed, J ;

Hoppenstead, D ;

Schultz, C ;

Ma, Q ;

Kujawski, MF ;

Neville, B ;

Messmore, H .

CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (09) :983-999

[5] Are the current guidelines for the acceptance of generic low molecular weight heparins adequate? [J].

Fareed, J ;

Bick, RL .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2003, 9 (04) :269-272

[6]

FAREED J, 1988, HAEMOSTASIS, V18, P33

[7] Generic forms of low-molecular-weight heparins: Some practical considerations [J].

Leong, W ;

Hoppensteadt, DA .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2003, 9 (04) :293-297

[8]

McCart GM, 2002, ANN PHARMACOTHER, V36, P1042

[9] Applying scientific criteria to therapeutic interchange: A balanced analysis of low-molecular-weight heparins [J].

Merli, GJ ;

Vanscoy, GJ ;

Rihn, TL ;

Groce, JB ;

McCormick, W .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2001, 11 (03) :247-259

[10] Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: A literature review [J].

Messmore, HL ;

Coyne, E ;

Wehrmacher, WH ;

Demir, AM ;

Fareed, J .

CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (09) :1001-1010

← 1 2 →